About GenXMap: built around the question

Built around the biological question

Biological research has split into three trades: experimental work, molecular data generation and computational analysis. A study can pass through several laboratories, a sequencing provider and an analysis team, each step technically sound, and still lose its biological context between them.

GenXMap was built to keep the three together — from study design and sample processing, through molecular characterisation, to analysis and interpretation — so that a programme produces coherent evidence rather than a set of datasets.

Our story

How the company was built

2020Founded in Marseille
By Raheleh Shayan , an immunologist with twenty-five years in cellular and molecular biology, across academic research, industry and contract research.
2020–2022Wet lab and technologies
The laboratory built up over two years: techniques and technologies brought in-house, and the first services structured.
2023Regional ecosystem
Joined Marseille Innovation, AFSSI and the wider Provence life-sciences network.
2024Inside the IHU
Laboratories integrated within the IHU Méditerranée Infection environment; public and private partnerships developed.
2025Internal R&D programme
Own research programme launched, and dry-lab and analysis capacity built alongside the bench.
2026OMICS4, proteomics and the clusters
OMICS4 launched as the production and booking platform; proteomics platform established and the specialist partner network set up; joining the Paris-Saclay Cancer Cluster and the Marseille Immunology Biocluster.
TodayOne team, one lead
Wet lab, bioinformatics and AI under one roof, and one scientific project lead per programme.

Why the question comes first

A biological question rarely maps to a single technology. We design the workflow around what has to be understood, measured or compared, and choose the platform afterwards.

Understanding a treatment response

May need genomic, transcriptomic and proteomic data read together, rather than one layer taken as a proxy for the rest.

Studying an infection

May need pathogen genomics, host response and microbiome, because the answer sits in the interaction and not in either side alone.

Sequencing, proteomics, single-cell, spatial approaches and computational models are tools; their value is in answering a question with the right level of evidence.

What we hold to

Principle 01

Biology stays connected

Design shapes the data, the data determines the analysis, and the analysis stays tied to the biological context, in one workflow rather than as separate deliverables.

Principle 02

Evidence converges

We integrate the relevant molecular layers to see whether signals point to the same biological process, and we separate biological effects from donor variability, technical variation and isolated findings.

Principle 03

Science stays traceable

Methods, parameters, software versions, thresholds and key decisions are documented throughout, so results can be understood, challenged and reproduced.

Marseille, and the network around it

GenXMap was founded in Marseille in 2020. Since 2024 its laboratories have operated within the IHU Méditerranée Infection environment, close to clinical and translational research. What we do not maintain in-house we run through selected specialist partners, under our own study design and coordination, so the client deals with one team. A5 Science contributes atomic force microscopy on biological particles in liquid conditions to the internal R&D programme.

We work with academic institutions, biotech companies and industrial R&D teams across six R&D sectors, on studies ranging from a single molecular analysis to an integrated multi-year programme.

See the six sectors we serve

Ecosystem

The network GenXMap runs on

Clusters, host institutions, funders, professional networks and specialist private partners. Open a category to see who is in it.

Clusters and biopoles04

GenXMap is a member of Eurobiomed and France Biotech, and is joining the Paris-Saclay Cancer Cluster and the Marseille Immunology Biocluster.

Host institutions and academic platforms02

The laboratories operate within the IHU Méditerranée Infection environment, alongside the genomics and medical-genetics platforms of the Marseille site.

Funding and innovation support05

GenXMap’s development has been supported by Bpifrance (2024, 2026), Région Sud (2025, 2026), RisingSUD, Business France and the Orange Femme Entrepreneuse programme (2025), with banking and business-development support from CEPAC, CIC and IODA Consulting. GenXMap is also a France 2030 awardee, through the regionalised PIA4 scheme.

Networks and memberships03

Professional networks and sector associations that connect GenXMap to the wider life-sciences community.

Specialist private partners07

What we do not maintain in-house we run through selected specialist partners, under our own study design and coordination, so the client deals with one team.

Samples and data

How your material and your data are handled

Set per study, written into the contract, and the same whoever runs the bench work.

01

Consent and bioethics

Patient-derived and clinical samples are handled under the consent and bioethics framework applicable to each study.

02

Where the data lives

Processed in France and elsewhere in the European Union, depending on the sensitivity of the data and the client’s requirements.

03

GDPR, in all cases

No exception, whichever platform or partner runs the measurement.

04

Access and retention

Access controlled per project; retention set by the study contract.

From question to decision

01

Biological question

What has to be understood, measured or compared.

02

Study design

Platforms and controls chosen after the question, not before.

03

Molecular characterisation

Wet lab run under one coordination.

04

Analysis and integration

Layers read together, not reconciled afterwards.

05

Interpretation

Evidence for the next R&D decision.

One team, from sample to biological insight